PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB-015 1-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF Collective Coll

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	Complete if Known	2
Application Number	09/724,961	Z
Filing Date	November 28, 2001	T
First Named Inventor	Schenk, Dale B.	
Group Art Unit	1771-1687	8
Examiner Name	Unassigned ACICHOLS	<u> </u>
Attorney Docket Number	15270J-004752US	3

			U.S. Patent Document	_		Pages, Columns, Lines,
Exam Initial		Cite No. ¹	Number Kind Code ² (if known)	Name of Patentes or Applicant of Cited Document	Oate of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
\simeq		196	6,150,091	Pandolfo et al.	11-21-2000	
	X_{-}	1	6,057,367	Stamler et al.	05-02-2000	
	1	2	5,958,883	Snow	09-28-1999	
2001	7	3	5,955,317	Suzuki et al.	09-21-1999	
F 2001	18	4	5,955,079	Mond et al.	09-21-1999	
	K 7	5	5,877,399	Hsiao et al.	03-02-1999	
. 4	1	6	5,869,093	Weiner et al.	02-09-1999	
DEMAR	1	7	5,869,054	Weiner et al.	02-09-1999	
	1	8	5,854,204	Findeis et al.	12-29-1998	
		9	5,851,998	Kline	12-22-1998	
		10	5,849,298	Weiner et al.	12-15-1998	
·		11	5,837,473	Maggio e al.	11-17-1998	
	<u> </u>	12	5,786,180	Konig et al.	07-28-1998	
		207	5,780,587	Potter	07-14-1998	
		13	5,753,624	McMichael et al.	05-19-1998	1
		14	5,750,349	Suzuki et al.	05-12-1998	
		197	5,744,368	Goldgaber et al.	04-28-1998	
		211	5,736,142	Sette et al.	04-07-1998	A 201
		15	5,733,547	Weiner et al.	03-31-1998	
		16	5,688,651	Solomon	11-18-1997	
		17	5,679,348	Nesburn et al.	10-21-1997	
		18	5,845,820	Hafter et al.	07-08-1997	
		19	5,641,474	Haffer et al.	06-24-1997	
		20	5,641,473	Hafter et al.	06-24-1997	
		21	5,612,486	McConlogue et al.	03-18-1997	
\Box		22	5,605,811	Seubert et al.	02-25-1997	ļ ,
		23	5,585,100	Mond et al.	12-17-1996	
\Box		24	5,571,500	Hafter et al.	11-05-1998	
		25	5,571,499	Hafler et al.	11-05-1996	
		175	5,441,870	Seubert, et al.	08-15-1995	
\vdash		28	5,434,170	Andrulis, Jr.	07-18-1995	,
		27	5,387,742	Cordell	02-07-1995	
1		181	5,270,165	Van Nostrand et al.	12-14-1993	
12	Z	28	5,231,000	Majocha et al.	07-27-1993	

Examiner Date Considered Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number, ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

Approved for use through 10/31/2002, OMB 005110031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

	,			
				_
Sheet	2	١,	f 44	

e required to respond to a collection	OF LIGHT STOP (TURSS LOCALISM & ASTO CIMB CO.	OCCUPANT DE				
Complete If Known						
Application Number	09/724,961	Ż				
Filing Date	November 28, 2001	Ш				
First Named Inventor	Schenk, Dale B.					
Group Art Unit	7777 647	뻥				
Examiner Name	Unassigned NICHOLS	25				
Attorney Docket Number	15270J-004752US	8				

	\sim						
		δT	29	5,220,013	Ponte et al.	06-15-1993	~
	~~	lΠ	30	5,208,036	Eppstein et al.	05-04-1993	
ı	4.	abla	31	5,192,753	McGeer et al.	03-09-1993	
,		ST	32	5,187,153	Cordell et al.	02-16-93	
	2001	F /	33	5,057,540	Kensil et al.	10-15-1991	
ı	<i>~</i> .	σ	198	5,004,697	Pardridge	04-0201991	
Ì	A06	0	34	4,666,829	Glenner et al.	05-19-1987	

				FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Office ³	eign Patent Do Number ⁴	Cument Kind Code ⁶ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
(2)	35	EP	911 036	A2		04-28-1999		Ω,
-	36	EP	868 918	A2		10-07-1998		0
	37	EP	863 211	A1		09-09-1998		0
	38	EP	845 270	A1		06-03-1998		
	39	EP	782 859	A1		07-09-1997		-0
	40	EP	683 234	A1		11-22-1995		0
\neg	41	EP	666 080	A1		08-09-1995		0
	42	EP	652 962	B1		12-16-1998	- NISA	- 0
	43	EP	639 081	B1		11-03-1999		ख्य
	44	EP	613 007	A2		08-31-1994	C	201 0 ✓
	45	EP	594 607	B1		08-27-1997	- UCD 2	. 0
	46	EP	561 087	B1		08-04-1999	600	√000
	47	EP	526 511	B1		05-28-1997	- 10	-0
	48	EΡ	506 785	B1		03-15-2000		7
	49	EP	451 700	A1		10-16-1991		U
	50	EP	440 619	B1		01-24-1996		0
	51	EP	359 783	B1		11-29-1995		-0-
	52	EP	276 723	B1		12-08-1993	,	8
	187	EP	783 104	A1		07-09-1997		0-
	199	PCT	00/77178	A1		12-21-2000		-8
	188	PCT	00/43049	A1		07-27-2000		-0-
	53	PCT	99/60024	A1		11-25-1999		0
1	54	PCT	99/60021	A2		11-15-1999		-0
\top	55	PCT	99/58564	A1		11-18-1999	*	- 0
نها.	56	PCT	99/06066	A2	——	02-11-1999		
X	57	PCT	99/27949	A1		06-10-1999		- 0

Signature Considered (Q-S-02	Examiner Signature	Date Considered	12-5-02
------------------------------	--------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

Sheet

Approved for use through 10/31/2002, OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
prespond to a collection of information unless it contains a uniformation of the contains a uniformation Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control rules.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

+

(use as many sheets as necessary)

99/27944

of | 11

PCT

	Complete if Known							
Application Number	09/724,961	_						
Filing Date	November 28, 2001	1						
First Named Inventor	Schenk, Dale B.	=						
Group Art Unit	4771-16472	چ						
Examiner Name	Unassigned-XJC140CS	Š						
	45070 004750 10	-						

	_		1	· · · · · · · · · · · · · · · · · · ·	
	First Named Inventor		Sche	nk, Dale B.	
Ì	Group Art Unit		4771	1647	ු න
	Examiner Name		Unas	eigned-XJC1+OCS	Š
	Attorney Docket Nu	mber		J-004752US	190
			·		-8
_		06-10-1	999		0
_		06-10-1	999		0.
_		01-07-1	999		
_		10-15-1	998		0-
_		02-26-1	COR		

/0116	188	59	PCT	99/27911	A1		06-10-1999			j
/ .	13	203	PCT	99/00150	A2		01-07-1999		þ	
1 SEP 2 4 7	11. 100	80	PCT	98/44955	Ā1		10-15-1998		0	-
		61	PCT	98/07850	A2	·	02-26-1998			l
(Z	\$	202	PCT	97/21728	A1 .		06-19-1997			\vdash
CAT .	RE	62	PCT	97/17613	A1		05-15-1997		5	ı
PART & TRADE		63	PCT	96/39176	A1		12-12-1996			
		208	PCT	96/28471	A1		09-19-1996		S (-)	J. C.
		64	PCT	96/25435	A1_		08-22-1996		K-9-	6
		65	PCT	96/18900	A1		06-20-1996		(A)	_
		66	PCT	95/31996	A1		11-30-1995	*		R
		200	PCT	95/12815	A1		05-11-1995		→ B,	7.6
		67	PCT	95/11994	A1_		05-04-1995			2
		68	PCT	95/11311	A1		04-27-1995		-0/	0
		69	PCT	95/05853	A1		03-02-1995			7
		70	PCT	95/04151	A2		02-09-1995		0	7
		201	PCT	94/28412	A1		12-08-1994			i
		71	PCT	94/03815	A1		02-17-1994			1
		72	PCT	94/01772	A1		01-20-1994			ĺ
		73	PCT	93/21950	A1		11-11-1993			
		74	PCT	93/18724	A1		09-02-1993		-0	i
		75	PCT	93/15760	A1		08-19-1993		0	ĺ
		76	PCT	93/14200	A1		07-22-1993		- 0 -	
		205	PCT	93/04194	A1		03-04-1993		0	l
		77	PCT	93/02189	A1		02-04-1993		0	1
		78	PCT	92/13069	A1		08-06-1992			ĺ
		79	PCT	92/06708	A1		04-30-1992		-8-	ĺ
		80	PCT	92/06187	A1		04-16-1992		<u>-</u>	
	\sqcup	81	PCT	91/19810	A1		12-26-1991		 	_
		82	PCT	91/16819	A1		11-14-1991		<u> </u>	İ
		83	PCT	91/12816	A1	7	09-05-1991		-0-	
		84	PCT	91/08760	A1		06-27-1991			
		85	PCT	90/12871	A1		11-01-1990			
		86	PCT	90/12870	A1		11-01-1990			
	L	87	PCT	89/01343	A1		02-23-1989		0	l
	lacksquare	88	PCT	89/06242	A1		07-13-1989			
•	المصل	89	PCT	89/06689	A1		07-27-1989			
		90	PCT	89/03687	A1		05-05-1989			ļ

Examiner Date Considered Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁸ Applicant is to place a check mark here if English language translation is attached.

Please	type	а	plus	sian	(+)	inside	this	box

|+|

PTO/SBJ08A (08-00)

PTO SOURCE (100-00)

Approved for use through 10/31/2002. OME 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/724,961 November 28, 2001 **Filing Date** First Named Inventor Schenk, Dale B. Group Art Unit 1771 |U|7 **Examiner Name** Unassigned DICHOL 15270J-004752US Attorney Docket Number

(use as many sheets as necessary)

Sheet 4 of 11

4	91	PCT	88/10120	A1	12-29-1988	- 0-
	92	GB	2 220 211	A	 01-04-1990	
ן מא	93	GB	2 335 192	Α	 09-15-1999	-8-



TC 1700

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 vl

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

+

(use as many sheets as necessary)

Sheet of | 11

Complete if Known				
Application Number	09/724,961	15		
Filing Date	November 28,2001	*K		
First Named Inventor	Schenk, Dale B.	Sc.		
Group Art Unit	4774 1642	~		
Examiner Name	Unassigned (C) (C)	3 5.5		
Attorney Docket Number	15270J-004752US			

l			OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		ľ
5	Examiner In Bals	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	000	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995).	0	ŀ
?	200 5	95	Associated Press, "Immune cells may promote Alzehimer's, a study finds," The Boston Globe (4/13/95).	0	
ΕI	AR OFFICE	96	BAUER et al., "Interleukin-6 and α-2-macroglobulin Indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	-0-	ŀ
		204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor- Transgenic Mice," <u>Eur. J. Immunol</u> , 29:345-354 (1999).	空	ŀ
		212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992).	EY ON	ł
		176	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):915-919 (2000).	雪	f
		97	BLASS, John P., "Immunologic Treatment of Alzhelmer's Disease," New England J. Medicing, 341(22):1694 (1999).	600/2900	ł
		98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	8	ŀ
		99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presentilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).	0	ł
		100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin, Genet Develop.</u> , 3: 102-109 (1993).	-8-	ŀ
		101	BRICE et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg, Psychiatry</u> , 56:112-115 (1993).	-a -	
		102	CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," <u>Soc.</u> <u>Neurosci, Abstracts</u> , 19:513.7 (1993).	0	
		213	CHEN et al. *An Antibody to β Amytold Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types, * Neuroscience Letters 125:223-228 (1991).	0	
		214	DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzhaimer's Disease," <u>Proc. Natl. Acad. Sci. USA. 10.1073/pnas.151261398</u> (2001).	0	
		103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 478-477 (1995).	-0-	
	W	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol.</u> <u>Sciences.</u> 59:341-347 (1983).	0	ŀ

	 	فالمنافئة المنافي والمنافي وال
Examiner	Date	10 5-00
Signature	Considered	10-3-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

+

(use as many sheets as necessary)

Sheet 6 of 11

Complete if Known			
Application Number	09/724,961		
Filing Date	November 28,2001		
First Named Inventor	Schenk, Dale B.		
Group Art Unit	777+ 1647		
Examiner Name	Unassigned MICHOLS UK		
Attorney Docket Number	15270J-004752US		

ф	1		105	FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).	7
	7	8	106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzhelmer Disease," Neurobiology of Aging, 17(5):809-815 (1996).	0
1	2007	8	107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse occytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).	0
	ARK ST		108	FLANDERS et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).	0
I			210	FRIEDLAND et al., "Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994).	전
Ī			109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(8514): 523-527 (1995).	E E
			215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with Aβ ₁₋₂₂ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).	CHECHNER
			110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TiP\$</u> , 13:108-113 (1992).	多數
			111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.,</u> 177:1181-1186 (1993).	decolizado d
Ī			112	GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998).	Ф
			113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3), 885-890 (1994).	-
			114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	0
ĺ			115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).	-0-
			116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996).	0
			190	GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," <u>J. Biol. Chem.,</u> 270(13):7013-7018 (1995).	0
			117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).	-0
			118	HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).	•
	1		119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: -97-119 (1997).	0
•					

Examiner Signatur	Sum	Date Considered	12-5-02
----------------------	-----	--------------------	---------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 vl

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	lase as many	3116613 83	Houssaly,
Sheet	7	of	11

Complete if Known				
Application Number	09/724,961			
Filing Date	November 28,2001			
First Named Inventor	Schenk, Dale B.			
Group Art Unit	1774- IUT "465			
Examiner Name	Unassigned MICHOLS			
Attorney Docket Number	15270.I-004752US			

					<u>~ (0 m</u>
01	PESS		120	HARDY, "Amyloid, the presentiins and Alzheimer's disease," TINS, 20(4): 154-159 (1997).	5
,	<u> </u>	3	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	14
3	4 2001	Ž.	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enclase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> . 1158:120-128 (1993).	
ENTS THA	EMARY		177	HELMUTH, L., "Further Progress on a β-Amytoid Vaccine," <u>Science</u> , 289:375 (2000).	
			122	HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	F-2-1
			123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. NeuroImmunology</u> , 52:147-152 (1994).	18092
			124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).	290
			125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J.</u> <u>Neuroimmunology</u> , 24:173-182 (1989).	-
			192	WATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species is Aβ42(43)," <u>Neuron</u> , 13:45-53 (1994).	0
			126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-218 (1982).	0
			216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-378 (1991).	-8-
			127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunokogy. 143:637-641 (1992).	0
			183	KATZAV-GOZANSKY et al., "Effect of monocional antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol, Appl. Biochem.</u> , 23:227-230 (1996).	0
			128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).	-0
			195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl- Terminus of the BA4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	0
			129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzhelmer's Disease," Neurodegeneration, 2:111-121 (1993).	0
			130	LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990).	-0-
	1	7	131	LANNFELT et al., "Alzhelmer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.,</u> 57:207-213 (1993).	0
				· · · · · · · · · · · · · · · · · · ·	

Examiner Signature	Dem	Date Consid r d	12	-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

STATEMENT BY APPLICANT

	(add as many	0,,00,00	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sheet	8	of	11

	Complete if Known
Application Number	09/724,961
Filing Date	November 28,2001
First Named Inventor	Schenk, Dale B.
Group Art Unit	ATTH- COFT
Examiner Name	Massigned PICHOLS
Attorney Docket Number	15270J-004752US

QX.	132	Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 3-28, 1999).	9	<i>Tr</i>					
2001	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997).	0						
AK OFFICE	134	LOPEZ et at., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).							
	218	MAJOCHA et al., *Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy,* The J. of Nuclear Med. 33:2184-2189 (1992).	(F)	-					
	217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	4	- '					
	135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro, Encap.</u> , 14(2): 197-210 (1997).	Official						
	136	MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).	A22	3					
	137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).	æ	_					
	206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.,</u> 287(24):17082-17088 (1992).	0	-					
	191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).							
	138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).							
	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).							
	140	PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996).	0	5					
	141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers." <u>Eur. J.</u> <u>Immunol.</u> , 25: 3521-3524 (1995).							
	142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).							
95	143	QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).							
	144	PASO-V.A., Grant application # 1 R43 AGI 5745-Q1-(publication data-unknown)- 1	-	72					
9	145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	-0	7					

LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Japanic

Examiner Signature	Slum	Date Considered	12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	(use as many	3110012 03	Hecessary)
Chack		- 1	44

Complete if Known						
Application Number	09/724,961					
Filing Date	November 28,2001					
First Named Inventor	Schenk, Dale B.					
Group Art Unit	1774-1647					
Examiner Name	Unassigned DICHOCS					
Attorney Docket Number	15270J-004752US					

_			^
ST.	146	ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (199).	520
2007	147	ROSSOR et al., "Alzheimer's Disease Families with Amytold Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	O
T STATE	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	40
	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.,</u> 268(33):25239-25243 (1983).	-0
TT	194	SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	0
	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," <u>J. Med. Chem.,</u> 38(21):4141-4154 (1995).	-80
	148	SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	0
	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000).	-8
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	þ
	151	SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403–409 (1993).	
	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease," <u>Scientific American, pgs. 68-78</u> (November, 1991).	0
	153	SELKOE, Dennis J., "In the Beginning," <u>Nature</u> , 354:432-433 (1991).	9
	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).	0
	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	
	156	SEUBERT et al., "isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	æ
	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).	B
	158	SMITS et al., "Prion Protein and Scrapie Suscaptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	0
36	159	SOLOMON et al., "Disaggregation of Alzheimer β-amytoid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).	-8
	200 6	147 209 189 194 178 148 149 150 151 152 153 154 155 156 157	ROSEOR et al., "Complement activation by β-amyfold in Alzheimer Disease," PNAS, 89:1-5 (1994) ROSSOR et al., "Alzheimer's Disease Families with Amyfold Precursor Protein Mutations," Annals of New York. Academy of Sciences. 695:198-202 (1993). RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones. J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1983). SAIDO et al., "Spatial Resolution of the Primary β-Amyfoldogenic Process Induced in Postischemic Hippocampus." J. Biol. Chem., 269(21):18235-18257 (1994). SCHENK et al., "Therapeutic Approaches Related to Amyfold-β Patient and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1985). SCHENK et al., "Immunization with amyfold-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400-173-177 (1999). SELKOE, D.J., "Imaging Alzheimer's Amyfold," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994). SELKOE, "Physiological production of the β-amyfold protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 16(10): 403-409 (1993). SELKOE, Dennis J., "Amyfold Protein and Alzheimer's Disease" Scientific American, pgs. 88-78 (November, 1991). SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991). SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:830-631 (1997). SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 326-327 (1992). SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992). SMITS et al., "Prion Protein and Scraple Susceptibility," Yel. Quart., 19(3): 101-105 (1997).

Examiner	Date 100 P CAN
Signature	Considered 2-5-0-2

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 vI

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	OIFE			
Hease type a plus sign (+) Inside this box Under the Paperwork Reduction Act of 1995, Name	S. Patent and T	Approved for use through 10/31/2002, rademark Office: U.S. DEPARTMENT (OF COMMERCE	主
Substitute for form 1449A/PTO	PRACEMAN	Complete if Known		0
	Application Number	09/724,961	70	ಶ
INFORMATION DISCLOSURE	Flling Date	November 28,2001	95	2001
STATEMENT BY APPLICANT	First Named Inventor	Schenk, Dale B.	වු	9
	Group Art Unit	4771-1647-	8	i

(use as many sheets as necessary) **Examiner Name** Unassigned—NICHOUS 15270J-004752US Sheet of Attorney Docket Number

80	160	SOLOMON et al., "Monoclonal antibodies inhibit in <i>vitro</i> fibrillar aggregation of the Alzheimer β-amyloid peptide." <u>PNAS</u> , 93:452-455 (1996).	PA.
	761	COLOMON, A. Pro-Rx (Protein Therapeutics), University of Tennessee Medical Center (publication date of parknown).	200
	162	SOLOMON, B., "New Approach Towards Fast Induction of Anti p-Amyroid Peptide immune Response," Department of Molecular Microbiology & Biolechifology, Telraviv University, Remet Aviv, Telraviv, Israel (publication de university).	1
70	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amytold peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996).	स
	184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).	æ
70	185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	0
	186	COLOMON et al., Activity of monoclonal ampodies in prevention of in vitro aggregation of their antigens," abstract from Department of Mulecular Microbiology and Biolectricity, Ter Ann University, Ter Ann Indian (publication data unknown).	þ
86	179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Ald in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	0
	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malarla", <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).	0
	STURCHLER-PIERRAT et al., "Two armyloid precursor protein transgenic mouse models with Alzheimer disease-lik pathology," PNAS, 94: 13287-13292 (1997).		
	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory def induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).		₽-
	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).	-6
	167	VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994).	-8-
	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	-8
	169	WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath, Exp. Neurology, 53(4):377-383 (1994).	4
	180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998).	4
	170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Blotech., 18:868-824 (2000).	4
7	171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ- Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).	0

Examiner Signature Consider d 12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box PTO/SB/08B (08-00) Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB gone of number. Under the Paperwork Reduction Act of 1996 MADENA Substitute for form 1449A/PTO Complete if Known Application Number 09/724,961 INFORMATION DISCLOSURE **Filing Date** November 28,2001 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor 4774 1647 Group Art Unit (use as many sheets as necessary) Unassigned PICHOL Examiner Name Sheet of 11 **Attorney Docket Number** 15270J-004752US WONG et al., "Neuritic Plaques and Cerebrovascular Amyro-Natl. Acad. Sci. USA. 82:8729-8734 ...

WOOD et al., "Amyloid precursor protein processing and A642 deposition in a transgenic mouse mode. ...
disease," PNAS. 94: 1550-1555 (1997).

-Human-Immunology & Cancer Program-brockure; from The University of Tenessee Medical-Center/ Graduate Schools of Medicine, Knowille, Tennessee (publication date unknown). WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. 172 219 173


Examiner Signature Considered 12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB peoples in Deber Substitute for form 1449A/PTO Complete if Known **Application Number** 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Schenk, Dale B. Group Art Unit 1647 (use as many sheets as necessary) Examiner Name Turner, Sharen Sheet of 6 15270J-004752US Attorney Docket Number

_				U.S. PATENT DOCUM	MENTS		
xaminer Initials *	Cite No.1	U.S. Patent Doc. Number Kind C (If kno	ode ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	RIV
767	267	6,294,171	B2	McMichael	09-25-2001		9
9	234	6,284,221	B1	Schenk, et al.	09-04-2001	REC	the real
$\neg \neg$	300	2001/0018053	A1	McMichael	08-30-2001		MINE
	230	6,262,335	B1	Hsiao et al.	07-17-2001	SEP	
	231	6,114,133		Seubert et al.	09-05-2000	7	2002
\top	221	5,989,566		Cobb et al.	11-23-1999	Training	1 🛇
	284	5,231,170		Averback	07-27-1993	TECHCEN !	FR FRANCIS
	242			Challiour et al.	N/A		T:: 1000/2
T	282	80/160,687		Chein	N/A-		
	206-	90/194,001		Holtzman et al.	N/A		IN)
	500	60/186,295		Rasmussen et al.	N/A'		لع
T	-299	80/254,485		Heltsmon et al.	N/A		١Ď
	907	60/254,408		Holtzman et al	N/A		1/-
16	200	99/441,140		- Colomon et al.	N/A		1:7

FOREIGN PATENT DOCUMENTS									
-	0	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,		
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T [®]	
3	243	PCT	01/39796	A2		08-07-2001			
	298	PCT	01/42306	A2	-	06-14-2001			
	301	PCT	01/62264	A2		03-01-2000			
	294	PCT	01/62801	A2		08-30-2001			
	240	PCT	00/43039	A1		07-27-2000			
70	227	PCT	95/11008	A2		04-27-1995			

	the state of the s		
Examiner Signature	Sem	Date Considered	12-5-02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1

PA3242256 v2 PA 3147648 v21

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

_	

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known **Application Number** 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor **Group Art Unit** 1647 (use as many sheets as necessary) WICHOZS **Examiner Name** Turner, Oharon Attorney Docket Number Sheet of 6 15270J-004752US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	77-
85	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <u>J. Mol.Biol.</u> , 225(4): 1075-1093 (1992).	<u></u>
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-4148 (1992).	- 20
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at . http://www.ida.gov/eber/vaccine/thimerosal.htm, lect-updated May 16, 2002.	
31	266	CHAPMAN, PAUL F., "Model behavior," <u>Nature</u> , 408:915-916 (2000).	
	222	Chemical Abstract-detebaser Abstract-of-Injection of Disaborn Mice with Seven-Chemical Adjuvants to Help—Determine Their Sefeny in User III Biologicals, "Chemical Abstract database. (Publication date unknown.) Main Property Pr	
为	302	CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Armyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999).	
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000).	
	286	CORDELL, B., *\$-Amyloid formation as a potential therapeutic target for Alzheimer's disease,* Ann. Rev. Pharmacol, <u>Toxicol.</u> , 34:69-89 (1994).	
	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).	
र्र	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the smyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998).	
	220	Dialog/Derwerk, Abstract of WPI-Ace No. 1997-054438/199706; Stable Vaccine compans. comprise a macrocyclic lactone, a milbernycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol, organic solvent and, saline or water. Derwent: WPI database(Publication date: unknown).	
SI	288	DUMERY et al., 'B-Amyloid protein aggregation; its implication in the physiopathology of Alzhelmer's disease, Pethol. Biol., 49:72-85 (2001).	
10	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	

Examiner Signature	Date Considered	12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1 PA3242256 v2 PA 3147648 v21

+

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademerk Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid CMB control number.

	Опродова в времи	CINTODG	3017A2 01 1830, 110 parsons	are required to respond to a consecution	OF REAL PROPERTY OF STATE OF S
Substitute for form 1449A/PTO					Complete If Known
				Application Number	09/724,961
INFORMATION DISCLOSURE				Filing Date	November 28, 2000
STATEMENT BY APPLICANT		First Named Inventor	Schenk, Dale B.		
				Group Art Unit	1647
(use as many sheets as necessary)		Examiner Name	Turner, Sharon NICHOUS		
Shoot	3	Of	6	Attorney Deaket Number	15270 1-004752118

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
7	228	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002).	_
	289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm, Sci.</u> , 22:2-3 (2001).	_
	246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).	_
	247	FRENKEL et al., "Immunization against Alzhelmer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000).	_
	248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmynology, 88:85-90 (1998).	_
	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-armyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of NeuroImmunology</u> , 95:136-142 (1999).	
	244	FRENKEL, et al., *Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody, * <u>J. of Neuroimmunology</u> , 106:23-31 (2000).	
	249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	_
	251	GARDAELLA et al., "Intact Alzheimer amytoid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem, Biophys, Res. Comm.</u> , 173:1292-1298 (1990).	
	252	GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzhelmer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999).	
	253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzhelmer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998).	
	303	GONZALES-FERNANDEZ et at., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," limmunglogy , 93:149-153 (1998).	
	237	GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
	254	GRUBECK-LOEBENSTEIN, et al., *Immunization with β-armyloid: could T-cell activation have a harmful effect?*, TINS, 23:114 (2000).	_
2	241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992).	_

Examiner Date Consi	dered 2-5-02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1 PA3242256 v2 PA 3147648 v 21

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** 09/724,961 INFORMATION DISCLOSURE **Filing Date** November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor Group Art Unit 1647 Tomer Sharen NICHOLS (use as many sheets as necessary) Examiner Name Sheet of 6 15270J-004752US Attorney Docket Number

xaminer	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
To	255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem, Biophys. Res. Comm.</u> , 211:1015-1022 (1995).	-
	229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interlaukin-2", Immunology, Vol. 78: 643-649 (1993).	-
	238	HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:61-69 (1991).	
	258	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:448-449 (1987).	_
	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	
	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995).	-
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Obs. in Chemical Biology</u> , 1:260-267 (1997).	-
	260	LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328–331 (2000).	-
	261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but n strlatum," Brain Research, 687:138-142 (1994).	
	263	MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Aβ ₄₂₍₄₃₎ " <u>Annals of Neurology</u> , 40:149-156 (1996).	-
	262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995).	-
	264	McGeer, et al., "Immunohietochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res</u> ., 31:428-442 (1992).	_
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-186 (1998).	_
	265	Mena, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol</u> , 89:50-58 (1995).	F
X	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989).	-

	Date Considered 12-5-02
--	-------------------------

EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 vl PA3242256 v2 PA 3147648 v 21

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete If Known				
Application Number 09/724,961				
Filing Date November 28, 2000				
First Named Inventor Schenk, Dale B.				
Group Art Unit 1647				
Examiner Name Tarrier, Sharon CHOCS				
Attorney Docket Number				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
kaminer itials "	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
M	250	NAKAMURA et al., "Histopethological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995).	-
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995).	
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998).	_
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acts.</u> , 104:480-488 (1965).	
	280	PARORIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem, Biophys. Res. Comm.</u> , 148:307-313 (1987).	_
	232	PETERSON, et al., * Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine- Derived Monoclonal Antibodies,* <u>Laboratory Animal Science</u> , 46(1):8-14 (1998).	
为	289	PHILIPPE, et al. "Generation of a monocional antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amytoid precursor protein," <u>J. of Neuroscience Res.</u> , 48:709-719 (1996).	
	304	Disease (publication # 1 R43 AGI 5748-01-(non-18dacted version), Immunotherapy of Alzheimer's Disease (publication date unknown).	
85	279	SAITO et al., "Vector-mediated delivery of ¹²⁶ I-labeled β-amyloid peptide Ab ¹⁻⁴⁰ through the blood-brain barrier and binding to Alzhelmer disease amyloid of the Aβ ¹⁻⁴⁰ vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).	_
	278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).	
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).	<u> </u>
	270	SCHENK, et al., "β-peptide immunization," <u>Arch. Nuerol.</u> , 57:934-936 (2000).	
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999).	
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on <i>in vitro</i> properties of the amyloid β-peptide as modeled with <i>N</i> -terminal decapeptide fragments," Int. J. Peotide Protein Res., 47:269-296 (1996).	_
X	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).	

Examiner Signature	Date Considered	12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, DC 20231.

PA 3244120 v1 PA3242256 v2 PA 3147648 v 21

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PTC)		Complete if Known		
				Application Number	09/724,961	
INFO	RMATION	DIS	CLOSURE	Filing Date	November 28, 2000	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Schenk, Dale B.	
				Group Art Unit	1647	
(use as many sheets as necessary)			necessary)	Examiner Name	Furner, Sharon NICHULS	
Sheet	6	of	6	Attorney Docket Number	15270J-004752US	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
80	276	TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996).	
60	274	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:587-579 (2000).	
		Wisconsin Alumni Research Poundation, "Injection of Newborn Mice with Seven Chemical Adjuvants-led-field"	1
	223 =	Determine Their Safety in Use in Biologicals 46. Gov. Res. Develop-Rep., 70(24), 58. (Publication date)	
56	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997).	
	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998).	
76	290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	

(ONSIDERED; DO NOT PRINT.

Examiner Signature	Date Considered	125-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1

PA3242256 v2 PA 3147648 v 21

PTO/SEAGLA (10-01)
Approved for use through 10/31/R002, OMB 0651-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE
Linder the Paperwork Reduction Act of 1995, no parsons expressing to respond to application of information unless it contains a valid CMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 09/724,981 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Dale B, Schenk Art Unit (uze as many sheets as necessary) 🐬 🦠 Examiner Name Sharon Turner 101 of 13 Attorney Docket Number 15270J-004752US Sheet.

		•	U.S. P	ATENT DOCUMEN	TS "	<u> </u>	
			Document Number			< -	
	niner's tials	Cite No.	Number Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, C Lines, V Relevant i or Rel Figures	Vhere assages event
C	B	326	2002/0136718 A1~	09-26-2002	Raso		
		325	2001/0102261 A1	08-01-2002	Raso	.~4	
		308	6,417,178 B1	07-09-2002	Klunk-et al.		
		267	6,294,171 B2	09-25-2001	McMichael	Sp.	
		234	6,284,221 B1	09-04-2001	Schenk, et al.		**
		300	2001/0018053 AT	08-30-2001	McMichael		-
		230_	6,262,335 B1-	07-17-2001	Hslao et al:	114	
		305	09/724,842	11-28-2000	Chalifour et al.		
_		231	6,114,133	09-05-2000	Saubert et al.		
	·	221	5,989,566	11-23-1999	Cobb et al.		
		283	09/441,140 -	11-16-1999	Solomon et al		
		321	5,837,672	11-17-1998	Schenk et al.		
7	-	320	5,593,846-	01-14-1997	Schenk et al.	4,2	
C	2	284	5,231,170	07-27-1993	Averback .		
<u> </u>		-242-	60/168,504		Chalifour et al.		
		282	60/169,687	N/A	- Chaln		- 6
		295	80/184,601	, <u> </u>	Holtzman et al.		
		296	80/254,465	- N/A -	Holtzman et al.		,
		287	80/254,498	. NA	Holtzman et al.		
		299	00/106,205	N/A ²	Rasmussen et al.		

	·····		_
Examiner	7 4 ** 0.	Date // Oct > -2	
Examiner Signature	Collins	Considered 4 24 2005	
			_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPSP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). § Kind Codes of U.S. Patant Documents at www.uspig.gov or MPSP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.S). § For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. § Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. § Applicant is to place a check mark here if English language Translation is etached.

Burden Hour Statement: This form is settinged to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORWS TO THIS ADDRESS, SEND TO: Assistant Commissioner for England Machineter Inc. 20284

Received from < 16503262422 > at 2/18/03 9:04:00 PM (Eastern Standard Time)

PTO/BB/03.A (10-01)
Approved for use through 10/31/2002. QMB 0651-b081
U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1865, no persons are reprinted to recover to a collection of information unless a combine a year of U.S. Patent and Description Act of 1865, no persons are reprinted to recover to a collection of information unless a combine a year of U.S. Patent and Description Act of 1865, no persons are reprinted to recover to a collection of information unless a combine a year.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE ... STATEMENT BY APPLICANT .

(use as many sheets as necessary) 13 of

	Complete If Known	<u> </u>	
-Application Number	09/724,961		_
Filing Date	November 28, 2000		_
First Named Inventor	Dale B. Schenk		_
Art Unit	1647		_
Examiner Name	Sharen Turner - NOICHOLS		
Attorney Docket Number	15270J-004752US	•	

			FORE	IGN PATENT	DOCUMENTS		<u>-</u>	
Examiner Initials*	Cite No.'	Forn Country Code ³	Number	Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Linds, Where Relevant Passages or Relevant Figures Appear	78
دروي	294	WO	01/62801	A2	08-30-2001			-
L	301	WO	01/82284 -	A2	03-01-2000			
	298	wo	01/42306	A2	08-14-2001	-		-
	243	WO	. 01/39798	A2	06-07-2001			
	322	WO	00/72880	A2, A3	12-07-2000			
	323	WO	00/7.2876	A2, A3	12-07-2000			
	324	wo	00/72870	A1	12-07-2000			
-	240	Wo	00/43039	A1	07-27-2000			
1	331	wo	99/06545	A2	11-02-1999			
Can	227	wo	95/11008	-A2	04-27-1995			-

	-	<u>·</u>		
Examiner Signature	Miss	Date Conside	ered 4/29	2003

EXAMINER: Initial if reference ganglemed, whether or not obtation is in conformance with MPEP 600. Draw fine through obtain if not in conformance and not considered, include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional), 2 Kind Codes of U.S. Patent Documents at www.usitio.gov or NPEP 901.04, 3 Kinds Office that issued the documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 5 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissions for

P roved for use through 10/31/2002 mark Office: U.S. DEPARTMENT	ni I

Approved for use through 10/31/2002. OMB 0651-0031

LLS. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a codesion of information unless a contains a valid CMB control number.

Substitute for form 1449B/PTO Complete If Known Application Number 09/724,981 INFORMATION DISCLOSURE Filing Date November 26, 2000 STATEMENT BY APPLICANT First Named Inventor Dale B. Schenk 1847 Art Unit (use as many sheets as necessary) Examiner Name Sheron Turner NICHOL Altomey Docket Number 15270J-004762US

. . . .

	OTH	ER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2	: : -
دىوى	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amylold Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992).		2/2
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging;" Reuters, April 20, 2001 7:58 PM ET.		7
V	327	CAMERON, "Recent Advances in Transgenic Technology," Molecular Biotechnology, 7:253-265 (1997).		102
(0)	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992).	į.	o Q
	224	Center for Biologics Evaluation and Research, U.S. Food and Brug Administration, Thirmerosal in Vaccines (Mercury in Plasma-Derived at Products), web site contents found at .	-01 P	60
	<u>۔۔</u> جث	http://www.fda.gov/cber/vaccine/tinimerosal.htm, last updated May 16, 2002.	.,	5
9	~ 266 6	CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2000).	_	6
(a)	222	Chemical Abstract detabase, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Sefety in Use		10 PO
	• -	in Biologicals," Chemical Abstract database. (Publication date unknown.)		Ü

Examiner Signature Considered 4/29/2003

EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 809, Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here it English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the includual case. Any comments on the amount of time you are required to camplete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark.

Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 V1

c

(). j.

FTO/SE/08B (19-01)

Approved for use through 10/31/2002, OMB 0881-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to repond to a collection of information unless it contains a visid OMB control funditor

OF DET FIRE PROPERTY PRODUCTION PROCESSING PROCESSING	THE REAL PROPERTY OF THE PERSON OF THE PERSO	Alterial legistration of a second of the sec	-
Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DIGGI CONTR	Application Number	09/724,961	
INFORMATION DISCLOSURE	Filing Date	November 28, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Dale B. Schenk	
•	Art Unit	1647	
(use as many sheets as necessary)	Examiner Name	Sharon Turner 1010HoL	5
Sheet 4 of 18	Attorney Docket Number	115270J-004752US	F

			_
رين	307	CHEN, et al. A learning deficit related to age and beta-amyloid plaques In a mouse model of Alzheimer's disease. Nature, 408(6815):975-9 (2000).	
	332	CHEN, et al.; "Neurodegenerative Alzheimer-like pathology in PDAPP, 717V→F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwen et al. Eds. 117:327-337 (1998).	اهٔ
	302	CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid 8-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999).	
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:268-274 (2000).	
	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset, Parkinson's disease; implications for pathogenesis and therapy," PNAS, 97(2):571-576 (2000)	ر ا
	286	CORDELL; B., "\$-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).	
	287	COSTA et.al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993).	_
8	293	DALY; et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998).	1.04

Ewominer) Date		1
Examiner	/ /// //	Date	1 4/20/2	
Signature	W/ Nul	Considered	1 11/21/2003	

*EXAMINER: initial if reference considered, whether or not obtation is in conformance with MPEP 609. Draw line through clarking 1/ not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English Janguage Translation is situated

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the heads of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Internation Officer, U.S. Petent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284821 v1

**

P.15

(10-01) בשטעפא, כדר? אבסרים להי של 10/31/2002, באספרים להי שם של 10/31/2002 באספרים להי 10/31/20

Complete If Known			
Application Number	09/724,961		
Filing Date	November 28, 2000 -	(1)	
First Named Inventor Dale B. Schenk			
Art Unit .	1847 -		
Examiner Name	Stranon Turner A) CHOL	\$	
Attorney Dacket Number	15270J-004752US		
	Application Number Filing Date First Named Inventor Art Unit Examiner Name	Application Number 09/724,981 Filling Date November 28, 2000 - First Named Inventor Dale B. Schenk Art Unit 1847 - Evaminer Name Strang Turner	

		-	٠,۱
220-	Diglog/Derwent, Abstract of WPI Acc No: 1697-054436/199706: Stable vaccine componer comprise a macrocyclic lectone, a milbernycin, an aventeetin, an artigan, a dispersing agent, an adjuvant, a water sol.	0.4	
	database: (Publication date unknown.)	,	l
318	DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001).	1 ;	4
288	DUMERY et al., *8-Amyloid protein aggregation; its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).	<u> </u>	
225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).		2
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)		1
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sd.</u> , 22:2-3 (2001).	-	
328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" <u>Alzhelmer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).	1	
246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).	1 1	
245 -	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of \$\beta\$-amyloid peptide is essential for modulation of fibrillar aggregation," \(\frac{1}{2} \) of Neuroimmunology, 95:136-142 (1999).		-
	288 225 226 289 328	 vaccine compons. comprise a macrocyclic lectone, a milbernycin, an avermeetin, an antigen, a dispersing agent, an adjuvant, a water colleganie solvent and ealine or water. Derwent File 361: Derwent WRI database. (Publication date unknown.) 318 DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001). 288 DUMERY et al., *β-Amyloid protein aggregation; its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001). 225 Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002). 226 Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002) 289 ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm. Sci., 22:2-3 (2001). 328 FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing:" Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). 246 FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001). 245 FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 	vaccine compans, comprise a macrocyclic lectone, a milbernyoln, an avermeotin, an antigen, a dispersing agent, an adjuvant, a water sell, organic solvent and selline or water, Derwent File 351; Derwent WRI database. (Publication date unknown.) 318 DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001). 288 DUMERY et al., *β-Amyloid protein aggregation; its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-86 (2001). 225 Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002). 226 Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002) 239 ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm. Sci., 22:2-3 (2001). 328 FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" Alzheimer's and Perkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). 246 FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001). 257 FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142

Examiner Signature Date Considered 4/29/03	<367

EXAMINER: Initial if reference-considered, whether or nel cliation is in conformance with MPEP 609. Crew kins through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Applicants unique attation designation number (options)). Applicant is to place a check mark here if English language Translation is exterhed

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradents! Office, Washington, DC 20281. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20281.

PA 3284821 V1

· i

PL.

l l	
PTO/\$12/04B (10)	-01\
Approved for use through 10/31/2002, OMB 0851-b	231
PROMOTE OFFICE ALL STREET OF COMMENT	cĖ :

U.S. Partent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1980, no persons are required to respond to a cofeccion of information unless it contains a visid CNB control number Substitute for form 1449B/PTO Complete If Known Application Number 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Dale B, Schenk 1847 Art Unit (use as many sheets as necessary) Examiner Name Sharon Turner Attorney Docket Number 15270 J-004752US Sheet

Ć.			1
CON	247	FRENKEL et al., "immunization against Alzheimer's #-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000).	
	248	FRENKEL et al., "N-terminal EFRH sequence of Alzhelmer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998).	
	244	FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000).	::
-	249	FRIEDLAND, et al., "Neurolmaging of Vessel Amyloid in Alzhelmer's Disease," in <u>Cerebrovascular Pathology in Alzhelmer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
-7,	251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem, Biophys. Res. Comm., 173:1292-1298 (1990).	_
*	252	GEDDES, "N-terminus truncated 8-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzhelmer's disease," Neurobiology of Aging, 20:75-79 (1999).	
	253	GIULIAN, et al., "The-HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998).	•
ريق	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of sometic mutants with hallmarks of antibody affinity maturation," Immunology, 93:145-153 (1998).	

`~					•			
Examiner Signature	6	14,1,90	Date Considered	11/4	4/29	103	, and the second	
								_

EXAMINER: Initial if reference considered, whether or not clistion is in conformance with MPEP 809. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique existen designation number (optional). * Applicant le to place a check mark hore if English language Translation is stached,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the included case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents, Washington, DC 20231.
PA 3284621 v1

210

PTC/SR/ord (Ip-0.1) =
Approved for use through 10/31/2002. OMS 0851-0091
Approved for use through 10/31/2002. OMS 0851-0091
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE:
Under the Paperwork Reduction Act of 1995, no parents are required to respond to a collection of information unless it contains a valid OAS control number.

Substitute for form 1449B/PTO		Complete if Known
WHODIA FIGURES PROGRAMES	Application Number	09/724,961
INFORMATION DISCLOSURE	Filing Date	November 28, 2000
STATEMENT BY APPLICANT	First Named Inventor	Dale B. Schenk
	Art Unit	1647
(use as many sheets as necessary)	Examiner Name	Sharon Turner NICHOUS
Sheet 7 of 13	Attorney Docket Number	15270J-004752U9

		_	~	چور در ۱۳۰۰ میرون در از این از برای در این	
	٠. در	JN.	237	GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	-
•			254	GRUBECK-LOEBENSTEIN, et al., "Immunization with B-amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000).	• 1.
٠.	•;		241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(8393):322-5 (1992).	-
			255	HARIGAYA, et al., "Modified amyloid & protein ending at 42 or 40 with different solubility accumulates in the brain of Alzhelmer's disease," Biochem, Biophys, Res, Comm., 211:1015-1022 (1995).	
	, ,	. 	- 229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993).	·
		•	236	HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid \$A4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:81-69 (1991).	-
			255	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:448-449 (1987)	
1	<i>y</i>		308	JANUS; et al. A beta peptide immunization reduces behavioural	,]
	'د'	છ	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997).	
	Exam	iner		/// Date /// 000	

Examiner Signature Considered

EXAMINER: Initial if reference cognidered, whether or not citation is in conformance with MPEP 600. Draw line through citation If not in conformance and not cansidered. Include of this form with need communication to applicant.

1 Applicant's unique oltation designation number (optional), 2 Applicant is to pisce a creek mark here if English language Translation is establed.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Tradement Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284821 v1

PTC/SE/08B (10-01)
Approved for use through 10/31/2002. OMB 0661-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1965, no persons are required to respond to a collection of information unless a collection at information unless a collection at information unless a collection of information unless a collection.

Bubsiliuts for form 1449B/PTO		Complete If Known	1
WEADNAMION PION OFFIE	Application Number	09/724,961	
INFORMATION DISCLOSURE	Filing Date	November 28, 2000	* • ~
STATEMENT BY APPLICANT	First Named Inventor	Dale B. Schenk	<u> </u>
3	Art Unit =	1647	
(use as many sheets as necessary)	Examiner Name	Sharon Turner NAICHOLS	V.
Sheet 8 of 13	Attorney Docket Number	15270J-004752US	フ

Con	334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," Molecular Microbiology, 5(7):1755-1767 (1991).	-
	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995).	- ·
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:280-287 (1997).	-
	260	LEMERE, et al., "Nasal As treatment Induces anti-As antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000).	١.
	261	MAK, et al., "Polycionals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain</u> <u>Research</u> , 667:138-142 (1994).	. 1
	263	MANN, et al., "Amyloid & protein (A&) deposition in chromosome 14-linked Alzheimer's disease; Predominance of A&42(48)," Annals of Neurology, 40:149-158 (1996).	ľ
	262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype." Neuroscience Letters, 198:105-108 (1995).	1 (5)
(De	335	MASLIAH et al., "8-Amyloid peptides enhance o-synuclein accumulation and neuronal deficits in a transgenic mouse model linking labeliner's disease and Parkinson's disease," PNAS 98(21):12245-12250 (2001).	9 1. 6

				<u> </u>
Examiner Signature	allisas	Date Considered	4/29/0	03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include topy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a chack mark hero if English language Translation is etlected

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time well very depending upon the nebds of the individual case. Any comments on the amount of time you are required to complete this form chould be sent to the Chief Information Officer, U.S. Patent and Tradembris. Officer, Washington, OC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, OC 20231.

PA 3284821 v1

-	
PTO/SB/01B (10-01)	•

Δ.

. 1

15270J-004752U8

Approved for use through 10/31/2002, OMB 0631-10/61

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QAIB control number Bubelitute for form 1449B/PTO Complete if Known Application Number 09/724,981 INFORMATION DISCLOSURE Pillng Date November 28, 2000 STATEMENT BY APPLICANT. First Named Inventor Dale B. Schenk Art Unit 1847 (use as many sheets as necessary) Sharen Turner NIGHOU Examiner Name

Attorney Docket Number

309 MATTSON, Cellular actions of beta-amyloid precursor protein and its. soluble and fibrillogenic derivatives. Physiol Rev. 77(4):1081-132 (1997).MCGEER, et al., "Immunohistochemical localization of beta-amyloid 264 precursor protein sequences in Alzhelmer and normal brain tissue by... light and electron microscopy," J. of Neuroscience Resi, 31:428-442 (1992).238 MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998). 265 MENA, et al., "Monitoring pathological assembly of tauland \$-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995). 310 MERLUZZI, et al. Humanized antibodies as potential drugs for . therapeutic use. Adv Clin Path. 4(2):77-85 (2000). MORGAN, et al. A beta peptide vaccination prevents memory loss in an 311 animal model of Alzheimer's disease. Nature, 408(6815);982-5 (2000). 233 MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989). 250 NAKAMURA et al., "Histopathological studies on sentile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. <u>Anim.,</u> 43:711-718 (1995). 268 NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amylold & protein (A&) subtypes (A&40 and A&42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus -monkeys," Neuroscience Letters, 201:151-154 (1995).

Examiner Signature	Date Considered 4/2	7/03

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation, a not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Ally comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trisdemark Office, Washington, DC 20281, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20251. · PA 3284821 VI

Applicant's unique citation designation number (optional). Applicant is to place a check muck here if English languistic Transtation is expeched

PTO/SB/08B (10-01)
Approved for use through 10/81/2002, OA/B 0851-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1998, no persons are required to respond to a collection of information unless it contains a welld CN/B control number

	Substitute for form 14498/PTO		Complete If Known	
	DISCOULTED LOCAL COLLEGE	Application Number	09/724,961	
	INFORMATION DISCLOSURE	Filing Date	November 28, 2000	
	STATEMENT BY APPLICANT	First Named Inventor	Dale B. Schenk	
		Art Unit -	1647	-
	(use as many sheets as necessary)	Examiner Name	Sharon Turner NICHOL	.3
-	8heet 10 of 13	Altorney Docket Number	15270J-004762US	
-				_

CZO	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-252 (1998).	
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Blochim. Bjophys. Acta</u> , 104:480-486 (1985).	
	329	NIEMANN, "Transgenic farm animals get off the ground," <u>Transgenic</u> Research 7:73-75 (1998).	
J	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Blochem. Biophys. Res. Comm.</u> , 148:307-313 (1987).	1 ^
	336	PERUTZ et al., "Amyloid fibers are water-filed nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	<u>-</u>
	232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Munne-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996).	
دهي	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 48:709-719 (1996).	
	-304	RASO, V.A., Grant application # 1 R43 ASI 5748-01 (non-reducted	
r. · · ·		version), "Immunetherapy of Alzheimer's Disease" (publication date unknown).	-
200	279	SÃITO et al., "Vector-mediated delivery of 12 labeled 6-amyloid peptide Ab140 through the blood-brain barrier and binding to Alzheimer disease amyloid of the As140 vector complex," PNAS USA, 92:10227-10231 (1995).	
Examiner		(21111 P) Date 479/03	

EXAMINER: Initial if reference considered, whether or not election is in conformance with MPEP 809, Draw line (through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademan Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284821 V1

Signature

Applicant's unique citation designation number (optional), Applicant is to place a check mark here if English language Translation is attached

91.

PTC/SB/0ED (1)-01)
Approved for use through 10/31/2002. ONB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwark Reduction Act of 1985, no parents are required to respond to a collection of information united & conteins a visid OMB control number.

Attorney Docket Number

Substitute for form 1448B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete If Known	•
Application Number	09/724,961	_
Filling Date	November 28, 2000	_
First Named Inventor	Dale B. Schenk	•
Art Unit	1847	_
Examiner Name	Sharen Turner NLCHOCB	

15270J-004752US

<5×	278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzhaimer's disease using anti- 8-protein monoclonal antibodies," Sappor Med. J., 60:309-320 (1991),	1, (;
	277	SASAKI et al., "Human chorold plaxus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997).	
	312	SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimers disease; a new frontier. DNA Cell Biol. 20(11):679-81 (2001).	
	270	SCHENK, et al., "β-peptide immunization," Arch. Nuerol., 57:934-938 2 (2000):	1
	313	SELKOE, The cell biology of beta-amyloid precursor protein and presentlin in Alzheimer's disease. Trends Cell Biol. 8(11):447-53 (1998).	
	330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," Arterioscier Thromb Vasc Biol., 20:1425-1429 (2000).	-
·	314	SIGURDSSON, et al. In vivo reversal of amyloid-beta esions in rat brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000).	
	315	SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 920:206-8 (2000),	
	337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," Trends in Blotech, 18(1):34-39 (2000).	
بق	319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2(8):595-8 (2001).	

		
Examiner Signature	Considered H	29/03

EXAMINER: Initial if reference code identity, whether or not citation is in conformance with MPEP 808, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement. This form is settinated to take 2.0 nouncile complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284821 V1

Applicant's unique sitation designation number (optional). Applicant is to piece a check mark here if English long large Translation is attached

12

Sheet .

PTO/SE/orb (1

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

Under the Payerwork Reduction Act of 1995, no parameter are required to respond to a collection of Information unless it contains a vell CMB control number Substitute for form 1448B/PTO Complete if Known Application Number 09/724,961 Filing Date November 28, 2000

First Named Inventor

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheels as necessary)

of 13

.1647 Art Unit Dominer Name Otraion Tolmers N (CHOC) 15270J-004752US Attorney Docket Number

Dale B. Schenk

			١-
CRO	316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis; implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998).	_
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999).	-
	338	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," The Journal of Neuroscience, 22(17):7380-7388 (September 1, 2002).	
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996).	
	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzhelmer's disease and systemic amyloidosis," PNAS, 92:4299-4303 (1995).	<u> </u>
	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).	13.
V	276	TJERNBERG et al., "Arrest of \$\betaamyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1998).	
	317	VEHMAS, et al. beta-Amylold peptide vaccination results in marked changes in serum and brain Abeta-levels in APPswe/IFS1 DeltaE9 mice, as detected by SELDI-TOF-based-ProteinChip® technology. DNA-Cell Biol. (11):713 21 (2001).	

`				_
Examiner Bignature	Mick	Date Considered	4/29/03	

EXAMINER: Initial If retirence considered, whether or not citation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered, include copy of the form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the release of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Officer, Weshington, DC 20231. DO NOT SEND PRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284621 v1

¹ Applicant's unique citation designation number (optional). S Applicant is to place a check mark here I/ English lenguage Translation is stached.

Application Number 09/724,95 Filing Date November, 26, 2000 First Named Inventor Date B. Schenk Art Unit 1647 Examiner Name Sharon Turner N/C/HOC Sheet 15 of 12 Atterney Docket Number 15270J-004752US WEINER et al., "Nasal administration of amyloid-\$\theta\$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). 223 WISCONSIN ALUMNI RECEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvents to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody-to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid & protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid & vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-18 (2001).	Application Number 09/724,98				U.S. Patent and Trader or required to respond to a confection of			PU (B)
STATEMENT BY APPLICANT Filing Date November, 28, 2000	STATEMENT BY APPLICANT	atute for form	1449B/P1	'0				-
STATEMENT BY APPLICANT First Named Inventor Dale B. Schenk	First Named Inventor Dale B. Schenk Ant Unit 1647 Examiner Name Sharon Furner N/C/FOX Bheet 13 of 12 Attorney Docket Number 15270-004752US WEINER et al., "Nasal administration of amyloid-\$\beta\$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Naurology, 48:567-579 (2000). 223 WISCONSIN ALUMNI, REGEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvents to Help Determine That Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid \$\beta\$ protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid \$\beta\$ vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	ORMA	TION	DISCLOSURE				-
Art Unit 1647 Examiner Name Sharon Termer NCCHOC Sheet 13 of 12 Atterney Docket Number 15270J-004752US 274 WEINER et al., "Nasal administration of amyloid-\$\theta\$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:587-579 (2000). 229 WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Miss with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Covt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody-to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid \$\theta\$ protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid \$\theta\$ vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	At Unit 1647 Examiner Name Sharon Turner N/C/HO(Bheat 13 of 12 Attorney Docket Number 15270J-004752US 274 WEINER et al., "Nasal administration of amyloid-\$\beta\$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). 229 WISCONSIN ALUMNI, REGEARCH FOUNDATION, "injection of Newborn Mise with Seven Chemical Adjuvents to Help Determine The Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid \$\beta\$ protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid \$\beta\$ vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).							_
Sheet 13 of 12 Attorney Docket Number 15270J-004752US	Sheet 13 of 12 Attorney Docket Number 15270J-004752US	* () Barer	H-1. H	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			CIPETIA	-≈.
Sheet 15 of 12 Atterney Docket Number 15270J-004752US 274 WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). 223 WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Sefety in Use in Biologicals", U-8. Gov4. Res. Develop Rep., 70(24), 56, (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclorial antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	Sheet 15 of 12 Attempt Docket Number 15270J-004752US 274 WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). 223 WISCONSIN ALUMINI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Hole Determine That Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56, (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	fine na	mony si	neels se negosseM		1	THE BY CHAY	4
WEINER et al., "Nasal administration of amyloid-\$\beta\$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-578 (2000). 223 WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Sefety in Use in Biologicals", U.S. Gavt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid \$\beta\$ protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid \$\beta\$ vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:587-578 (2000). 223 WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Miss with Seven Chemical Adjuvants to Holp Determine That Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication data unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).							~
cerebral amyloid burden in a mouse model of Alzhelmer's disease," Annals of Neurology, 48:567-579 (2000). 223 WISCONSIN ALUMNI; RESEARCH FOUNDATION, "Injection of Newborn Miss with Seven Chemical Adjuvants to Holp Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:587-578 (2000). 223 WISCONSIN ALUMNI; RESEARCH FOUNDATION, "Injection of Newborn Mise with Seven Chemical Adjuvants to Help Determine The Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid \$\beta\$ protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid \$\beta\$ vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	<u>. 1.10 </u>			- Armino Pocker (Antibet	- (02)00-0	177.02.00	=
cerebral amyloid burden in a mouse model of Alzhelmer's disease," Annals of Neurology, 48:567-579 (2000). 223 WISCONSIN ALUMNI; RESEARCH FOUNDATION, "Injection of Newborn Miss with Seven Chemical Adjuvants to Holp Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:587-578 (2000). 223 WISCONSIN ALUMNI; RESEARCH FOUNDATION, "Injection of Newborn Mise with Seven Chemical Adjuvents to Help Determine The Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).						}	: }
cerebral amyloid burden in a mouse model of Alzhelmer's disease," Annals of Neurology, 48:587-579 (2000). 223 WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Miss with Seven Chemical Adjuvants to Holp Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acts Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). 229 WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Miss with Seven Chemical Adjuvents to Help Determine The Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocional antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and Improved cognition," Nature Medicine, 7:18-19 (2001).		74	MENTS of all things			ide de annua -	7
Annals of Neurology, 48:587-579 (2000). 223 WISCONSIN ALUMNI; RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid \$ protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid \$ vaccination; reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	Annals of Neurology, 48:567-579 (2000). 223 Wisconsin Al-Umini, Research Foundation, "Injection of Newborn Mise with Seven Chemical Adjuvants to Help Determine The Safety In Use In Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	24 -	2/4					- [
Wisconsin ALUMNi RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Holp Determine Their Safety In Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclorial antibody to the human insulin receptor," J. Clin. invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	Wisconsin ALUMNI RESEARCH FOUNDATION, "injection of Newborn Mise with Seven Chemical Adjuvents to Helip Determine That Safety in Use in Biologicals", U.S. Covt. Res. Develop Rep., 70(24), 50. (Publication date unknown.) WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. invest., 100:1804-1812 (1997). YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	4]			r wansiin	a d Miseese'	T
Newborn Miss with Seven Chemical Adjuvants to Holp Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	Newborn Miss with Seven Chemical Adjuvants to Help Determine That Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved		<u>-</u>	CHILDIA OF LIERICANA	70.501-01.0 (2000).			4
Newborn Miss with Seven Chemical Adjuvants to Holp Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	Newborn Miss with Seven Chemical Adjuvants to Help Determine The Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	-	223	WISCONSIN ALUMN	HRESEARCH FOUND	ATION, "Ir	lection of	
Safety in Use in Biologicate", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acts Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	Safety in Use in Biologicals", U.S. Govt. Res. Develop Rep., 70(24), 56. (Publication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acts Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved							rl
 50. (Fublication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved 	 56. (Fublication date unknown.) 275 WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved 		. 1					-
the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," <u>J. Clin. Invest</u> ., 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," <u>J. Clin. Invest</u> ., 100:1804-1812 (1997). YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	}						1
the primate blood-brain barrier in vivo with a monoclorial antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	the primate blood-brain barrier in vivo with a monocloral antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved					<u>-</u> -		╅
human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). 292 YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved		275					1
YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved		}) -
β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	β protein, possibly showing a disappearing stage of senile plaques," Acta Nauropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	i	İ	human insulin recepti	or," <u>J. Clin. Invest.,</u> 100	:1804-181	2 (1997).	-
β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	7	200	VAMACUICHI MALI	Niffuna alaguaa aasaala	م مافتده المحد		
Acts Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	Acts Neuropathol., 95:217-222 (1998). 290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	1	292					Ĺ
290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	290 YOUNKIN, "Amyloid β vaccination: reduced plaques and improved	1/ 1				waa or se	une hiadaesi	1
		*		Total (Textlopatrion, o	VIA 11-222 (1884).			1
		(if	290	YOUNKIN, "Amyloid,	β vaccination; reduced	plaques a	nd Improved	
			1					
		- <u>-</u>						╼╫╌
		-		•	_	-	•	
		-	•		a '		•	Į
		3	•		• .			
		3	•		•			
		<u> </u>	•	·	•			
		-	•		•			
			•	•••		1.		-
			•					
			•				7. •	
			,				₩	-
			•				17. ·	
			·					-

Applicant's unique citation designation number (optional). Applicant is to place a check mark here it English longuage Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Tradement Office, Washington, OC 2029t. DO NOT SEND FEES OR COMPLETED PORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2029t.

PA 3284621 v1

Received from < 16503262422 > at 2/18/03 9:04:00 PM [Eastern Standard Time]

PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Schenk, Dale B.

1647

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known **Application Number** 09/724.961 INFORMATION DISCLOSURE Filing Date November 28, 2000

Art Unit

First Named Inventor

(use as many sheets as necessary)

STATEMENT BY APPLICANT

Examiner Name Nichols Page of 6 15270J-004752US Attorney Docket Number

			U.S. PATENT D	OCUMENTS	
Examiner	Cite No.1	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CNS	360	2003/0073655 A1	04-17-2003	Chain	
1	370	2003/0068325 A1	04-10-2003	Wang	
A	378	2002/0197258 A1	12-26-2003	Ghanbari et al.	
3	366	2002/0187157 A1	12-12-2002	Jensen et al.	
1	377	2002/0168377 A1	11-14-2002	Schaetzl	
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	395	2002/0160394 A1	10-31-2002	Wu	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Gefter et al.	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	376	2002/0086847	07-04-2002	Chain	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	381	2001/0021769 A1	09-13-2001	Prusiner	
	401	6,284,533 B1	09-04-2001	Thomas	
	345	2002/0077288 A1	06-21-2001	Frangione	
	346	5,935,927	08-10-1999	Vitek et al.	
	382	5,846,533	12-08-1998	Prusiner	
	353	5,824,322	10-20-1998	Balasubramanian	
	357	5,776,468 B1	07-07-1998	Hauser et al.	
	380	5,750,361	05-12-1998	Prusiner et al.	
	373	5,721,130	02-24-1998	Seubert et al.	
	356	5,622,701	04-22-1997	Berg	
N/	358	5,583,112 B2	12-10-1996	Kensil et al.	
A	403	5,464,823	11-07-1995	Lehrer et al.	
Q	402	4,713,366	12-15-1987	Stevens	
			<u> </u>		

Examiner Date Considered Signature

EXAMINER: Initial if reference ensidered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Enter

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Er Man EN Complete if Known Application Number 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor 1647 Art Unit (use as many sheets as necessary) Examiner Name **Nichols** 15270J-004752US Page of Attorney Docket Number

FOREIGN PATENT DOCUMENTS								
Examiner	examiner Cite	For	eign Patent Docume	nt		Name of Patentee or	Pages, Columns, Lines, Where Relevant	·
Initials*	No.1	Country Code ³	Number ⁴ Kind	Code ^b (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Te
ट्युष्ट	343	EP	1 172 378	A1	01-16-2002			1
1	351	wo	02/34878	A2	05-02-2002			4
	352	wo	02/34777	A1	05-02-2002			10
	341	wo	02/03911	A2	04-07-2001			
	344	wo	01/90182	A2	11-29-2001			
A-	348	wo	01/77167	A2	10-18-2001			
حوي	383	wo	97/10505	A1	03-20-1997			10
		T						

Examiner Signature	allier	Date Considered 1/6/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copylof this form with next communication to applicant.

Applicant's unique citation designation number (optional). Xind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Xind of document by the appropriate symbols as indicated on the document at the MIPO Standard ST.43. If sensible to believe a short with the St. 45. If sensible to the serial number of the patent document. under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commants on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute to CARBELL

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/724,961 **Filing Date** May 26, 2000 First Named Inventor Schenk, Dale B. Art Unit 1647 Examiner Name **Nichols** Attorney Docket Number 15270J-004752U\$

(use as many sheets as necessary) Page

	NON PATENT LITERATURE DOCUMENTS						
Examiner Cite No.1		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
⊘ Û 391		AGUZZI et al., "Prion research: the next frontiers," Nature, 389:795-798 (1997).					
393		AKIYAMA et al., "Inflammation and Alzheimer's disease," Neurobiology of Aging, 21:383-421 (2000).					
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," Glia, 25:324-331 (1999).					
	404	BENJAMINI and LESKOWITZ, from <i>IMMUNOLOGY A Short Course</i> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.					
	349	CHECK, "Battle of the Mind," Nature, 422:370-372 (March 2003).	-				
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," Biochem, J., 320:53-570 (1996).					
	363	DODART, "immunotherapy for Alzheimer's disease: will vaccination work?" <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).					
	386	FRATUTSCHY et al., "Effects of Injected Alzheimer β-amyloid cores in rat brain," <u>PNAS</u> , 88:8362-8366 (1991).					
	364	FURLAN et al., "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003).					
	388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," Ann. Rev. Med., 46:57-65 (1995).					
M	397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," PNAS, 96:3108-3113 (1999).					
CO	374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," Alzheimer Disease and Associated Disorders, 9(1):47-51, Raven Press, Ltd., New York (1995).					

Examiner	(11.7)	Date	11/1/07
Signature	A	Considered	11/6/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. VUnder the Paperty

Substitute for form 1449/PTO

PTO/SB/08B (04-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/724.961 Filing Date May 26, 2000 **First Named Inventor** Schenk, Dale B. Art Unit 1647 **Examiner Name Nichols** 15270J-004752US Attorney Docket Number

(use as many sheets as necessary) Page of 6

<u> </u>			NON PATENT LITERATURE DOCUMENTS			
Examiner Initials * No.1			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β-Amyloid Peptide (1-43) in Transfected 293 Cells, Blochemical and Blophysical Research Communications, 220:710-718 (1996).			
		347	JORBECK et al., "Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Infection and Immunity, May:497-502 (1981).			
		389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567- 1582 (2002).			
		367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid \$\beta\$-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," PNAS, 98(18):10273-10278 (2001).			
		359	MUNCH et al., "Potentional neurotoxic inflammatory response to Aß vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087.	_		
		355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	_		
		354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.			
		350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).			
		398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " <u>J. Mol. Med.</u> , 7:703-707 (2001).			
V		406	PAN et al., "Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide," <u>Exp.</u> <u>Biol. Med.</u> , 227(8):609-615 (2002).			
Q	N	394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scraple and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).			

Examiner Signature Date Considered 11/6/23	 			 		
Signature / / / / / / V/N	 102	11/1		11 :1	/ /	
	 <u>U</u>	110	Considered	<u> Nel X</u>	1	Signature

EXAMINER: Initial if reference considered, whether or net citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include cody of this form with next communication to applicant.

Applicant's unique district designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete. Including gathering, preparing, and surfacility the completed application form to the USPTO. Time will vary depending upon the individual case. According to the application of the uspections for reducing this burden, should be sent to individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

COLLINA Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known	
Application Number	09/724,961	
Filing Date	May 26, 2000	
First Named Inventor	Schenk, Dale B.	
Art Unit	1647	
Examiner Name	Nichols	
Attorney Docket Number	15270J-004752US	
	· · · · · · · · · · · · · · · · · · ·	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
(30)	396	SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003).	_
	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).	
1	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," Neurobiology of Aging, 23:1001-1008 (2002).	
	368	SIPE, "Amyloidosis," <u>Annu. Rev. Blochem.</u> , 61:947-975 (1992).	-
	369	SPOONER et al., "The generation and characterization of potentially therapeutic A8 antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).	
	361	SU et al., "Intravascular infusions of soluble \$\textit{\beta}\-amylold compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," Brain Research , 818:105-107 (1999).	
	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival In Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).	_
	399	TAN et al., "Amyloidosis," Histopathology, 25:403-414 (1994).	
	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein," Neuroscience Letters, 2002:77-80 (1995).	_
W.	387	WELDON et al., "Neurotoxicity of A# Peptide: Confocal Imaging of Cellular Changes Induced by Amyloid in Rat CNS In Vivo," <u>Society for Neuroscicence Abstracts</u> , 22(Part 1) (1996).	-
W.	385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):-574-587 (2002).	

Examiner Signature	1/19	Date Considered	11/1/102	
J.g. Later				

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.